Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

Jonathan Cohen; Alison Palumbo; Jason Wing; Michael C. Heinrich

doi:10.1080/10428194.2020.1768380

Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

Jonathan Cohen, Alison Palumbo, Jason Wing, Michael C. Heinrich

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	2511-2514
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	61
Issue number	10
DOIs	https://doi.org/10.1080/10428194.2020.1768380
State	Published - Aug 23 2020

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2020.1768380

Cite this

Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes. / Cohen, Jonathan; Palumbo, Alison; Wing, Jason et al.
In: Leukemia and Lymphoma, Vol. 61, No. 10, 23.08.2020, p. 2511-2514.

Research output: Contribution to journal › Letter › peer-review

@article{b6d87579a7af441390336ae93cc09045,

title = "Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes",

author = "Jonathan Cohen and Alison Palumbo and Jason Wing and Heinrich, {Michael C.}",

year = "2020",

month = aug,

day = "23",

doi = "10.1080/10428194.2020.1768380",

language = "English (US)",

volume = "61",

pages = "2511--2514",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "10",

}

TY - JOUR

T1 - Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib

T2 - experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

AU - Cohen, Jonathan

AU - Palumbo, Alison

AU - Wing, Jason

AU - Heinrich, Michael C.

PY - 2020/8/23

Y1 - 2020/8/23

UR - http://www.scopus.com/inward/record.url?scp=85085997858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085997858&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1768380

DO - 10.1080/10428194.2020.1768380

M3 - Letter

C2 - 32452280

AN - SCOPUS:85085997858

SN - 1042-8194

VL - 61

SP - 2511

EP - 2514

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 10

ER -

Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this